The insulin-like growth factor-1 and expression of its binding protein-3 in chronic hepatitis C and hepatocellular carcinoma

Adamek, Agnieszka; Kasprzak, Aldona; Mikos, Hanna; Przybyszewska, Wiesława; Seraszek‐Jaros, Agnieszka; Czajka, Arkadiusz; Sterzyńska, Karolina; Mozer‐Lisewska, Iwona

doi:10.3892/or.2013.2546

Cited by 14 publications

(8 citation statements)

References 44 publications

(71 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our patients, serum concentration of IGF1 showed no differences related to age nor sex as agreed by Kasprzak et al [21] and Adamek et al [22] who stated same results as ours. Upon recording IGF1 level in our HCC patients, it decreased significantly to reach a range of 12-67 mg/dL with a mean level 48.2 mg/dL in comparison to normal reference range (74-300 mg/dL).…”

Section: Discussionsupporting

confidence: 92%

Evaluation of serum protein markers in diagnosis of hepatocellular carcinoma and carcinogenesis risk assessment in chronic liver disease patients

Hegazy¹,

Eissa²,

Sorour³

et al. 2017

APJTD

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Evaluation of serum protein markers in diagnosis of hepatocellular carcinoma and carcinogenesis risk assessment in chronic liver disease patients

Hegazy¹,

Eissa²,

Sorour³

et al. 2017

APJTD

View full text Add to dashboard Cite

“…In addition, reduced levels of IGFBP-3 expression may be a risk factor for advanced clinicopathological classification and poor prognosis in patients with ESCC and may, therefore, serve as a useful marker for prognostic evaluation (14). Furthermore, Adamek et al (35) reported that an estimation of the IGF-1:IGFBP-3 ratio may provide additional non-invasive markers for hepatitis C virus (HCV)-associated liver injury. Aleem et al (36) demonstrated that serum IGFBP-3 levels are reduced as hepatic dysfunction progresses, and may be correlated with the development of HCC in patients with chronic HCV and liver cirrhosis.…”

Section: Discussionmentioning

confidence: 99%

Low expression levels of insulin-like growth factor binding protein-3 are correlated with poor prognosis for patients with hepatocellular carcinoma

Yan

Yang

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Insulin-like growth factor binding protein-3 (IGFBP-3) has previously been identified as a putative tumor suppressor gene. The present study investigated the clinical and prognostic significance of IGFBP-3 expression levels in patients with hepatocellular carcinoma (HCC). Immunohistochemistry (IHC) probing for IGFBP-3 was performed on paraffin-embedded tissue samples obtained from 120 patients with HCC, including tissue samples from 120 primary cancer sites and 50 matched adjacent non-malignant sites. Receiver-operator curve (ROC) analysis was used to determine the cut-off scores for the presence of IGFBP-3-positive tumor cells and to estimate the survival time of the patients. The threshold for marking the positive expression of IGFBP-3 was 65%, based on the area under the ROC. Positive expression of IGFBP-3 was observed in 65/120 (54.2%) of the HCC tissues, and in 36/50 (72%) of the adjacent non-malignant liver tissues. Low levels of IGFBP-3 expression were correlated with tumor size (P=0.003), tumor multiplicity (P=0.044), node (P=0.008), metastasis (P=0.001) and clinical stage (P=0.001), as well as reduced survival time (P= 0.015). Using univariate survival analysis, a significant direct correlation between high and low IGFBP-3 expression levels, and patient survival time (mean survival time high IGFBP-3, 39.4 vs. low IGFBP-3, 18.7 months) was identified. Kaplan-Meier analysis demonstrated that IGFBP-3 expression levels and patients survival time were significantly correlated (P<0.001). Multivariate analysis revealed IGFBP-3 expression to be an independent parameter (P= 0.003). Therefore, low levels of IGFBP-3 expression are associated with advance clinicopathological classification and may be a predictor of poor survival in patients with HCC. Furthermore, these findings suggest that IGFBP-3 may serve as an independent molecular marker for the evaluation of prognosis in patients with HCC.

show abstract

“…The studies on tissue mRNA and protein levels of human HCC specimens generally confirm the epidemiologic data. All tested HCC tissues showed a decrease in IGF1 expression (mRNA, protein) [ 161 , 162 , 163 ]. Significant correlations between reduced IGF1 expression in primary lesions and poor differentiated HCC and portal vein infiltration were also found [ 163 ].…”

Section: Evidence From Epidemiologic and Clinicopathological Studimentioning

confidence: 99%

Insulin-Like Growth Factor (IGF) System in Liver Diseases

Adamek

Kasprzak

2018

IJMS

Self Cite

193

127

View full text Add to dashboard Cite

Hepatocyte differentiation, proliferation, and apoptosis are affected by growth factors produced in liver. Insulin-like growth factor 1 and 2 (IGF1 and IGF2) act in response to growth hormone (GH). Other IGF family components include at least six binding proteins (IGFBP1 to 6), manifested by both IGFs develop due to interaction through the type 1 receptor (IGF1R). The data based on animal models and/or in vitro studies suggest the role of IGF system components in cellular aspects of hepatocarcinogenesis (cell cycle progression, uncontrolled proliferation, cell survival, migration, inhibition of apoptosis, protein synthesis and cell growth), and show that systemic IGF1 administration can reduce fibrosis and ameliorate general liver function. In epidemiologic and clinicopathological studies on chronic liver disease (CLD), lowered serum levels, decreased tissue expression of IGF1, elevated production of IGF1R and variable IGF2 expression has been noted, from the start of preneoplastic alterations up to the developed hepatocellular carcinoma (HCC) stage. These changes result in well-known clinical symptoms of IGF1 deficiency. This review summarized the current data of the complex role of IGF system components in the most common CLD (nonalcoholic fatty liver disease, cirrhosis, and hepatocellular carcinoma). Better recognition and understanding of this system can contribute to discovery of new and improved versions of current preventive and therapeutic actions in CLD.

show abstract

The insulin-like growth factor-1 and expression of its binding protein-3 in chronic hepatitis C and hepatocellular carcinoma

Cited by 14 publications

References 44 publications

Evaluation of serum protein markers in diagnosis of hepatocellular carcinoma and carcinogenesis risk assessment in chronic liver disease patients

Evaluation of serum protein markers in diagnosis of hepatocellular carcinoma and carcinogenesis risk assessment in chronic liver disease patients

Low expression levels of insulin-like growth factor binding protein-3 are correlated with poor prognosis for patients with hepatocellular carcinoma

Insulin-Like Growth Factor (IGF) System in Liver Diseases

Contact Info

Product

Resources

About